| Vol. 12.33 – 25 August, 2020 |
| |
|
|
| Motivated by the enormous advantages of Zn‐based metal-organic framework‐derived nanocarbons, C‐ZnO nanocarbons‐modified fibrous scaffolds for stem cell‐based osteogenic differentiation were constructed. [Small] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists showed that circRNA-vgll3 originating from the vgll3 locus markedly enhanced osteogenic differentiation of adipose-derived mesenchymal stem cells. [Cell Death & Differentiation] |
|
|
|
| Investigators found lipopolysaccharide significantly increased inflammatory factors, administration of exosomes released by human umbilical cord MSCs successfully improved lung morphometry. [Cell Death & Disease] |
|
|
|
| Researchers demonstrated that differentiation of MSCs resulted in distinct membrane viscosities, that reflected the change in lipidome of the cells following differentiation. [Scientific Reports] |
|
|
|
| | Adherent culture was used to isolate and purify rat MSCs. The status, proliferation and differentiation of MSCs were detected by hematoxylin-eosin staining, MTT, colony formation, flow cytometry and directional differentiation. [Cell Cycle] |
|
|
|
| | WTAP was found to be highly expressed in osteosarcoma tissue and it was an independent prognostic factor for overall survival in osteosarcoma. [Cell Death & Disease] |
|
|
|
| The authors investigated the vascular nature of lung-resident mesenchymal stem cells using healthy human lung tissue. [Stem Cells Translational Medicine] |
|
|
|
| MSC isolates were derived from low-purity islet fractions and expanded in platelet lysate-supplemented medium or in commercially available xenogeneic-free medium. [Cytotherapy] |
|
|
|
|
| Researchers review the recent clinical trials and the therapeutic benefits of MSCs in coronavirus‐induced acute respiratory distress syndrome. [Stem Cells Translational Medicine] |
|
|
|
|
| NantKwest, Inc. announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic. The two product candidates currently in development under the agreement are a mesenchymal stem cell therapeutic from NantKwest, whose goal is to reduce the time a critically ill patient spends on a ventilator; and a COVID-19 vaccine product from ImmunityBio, which is anticipated to soon enter into a Phase I clinical trial. [NantKwest, Inc. ] |
|
|
|
|
|
|
|
| Pennsylvania State University – Philadelphia, Pennsylvania, United States |
|
|
|
| University of North Carolina at Chapel Hill – Chapel Hill, North Carolina, United States |
|
|
|
| University of Connecticut Health – Farmington, Connecticut, United States |
|
|
|
| Heidelberg Institute for Stem Cell Technologies and Experimental Medicine – Heidelberg, Baden-Württemberg, Germany |
|
|
|
|